# Topical Rapamycin to Erase Angiofibromas in TSC

> **NCT01526356** · PHASE2 · COMPLETED · sponsor: **The University of Texas Health Science Center, Houston** · enrollment: 179 (actual)

## Conditions studied

- Angiofibromas
- Tuberous Sclerosis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Rapamycin
- **DRUG:** Rapamycin

## Key facts

- **NCT ID:** NCT01526356
- **Lead sponsor:** The University of Texas Health Science Center, Houston
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 179 (ACTUAL)
- **Last updated:** 2020-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01526356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01526356, "Topical Rapamycin to Erase Angiofibromas in TSC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01526356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*